BriaCell Therapeutics Corp. Quarterly Deferred Tax Assets, Net of Valuation Allowance in USD from Q2 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
BriaCell Therapeutics Corp. quarterly Deferred Tax Assets, Net of Valuation Allowance history and growth rate from Q2 2021 to Q2 2023.
  • BriaCell Therapeutics Corp. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending July 31, 2023 was $45.2K, a 6.64% decline year-over-year.
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2023 $45.2K -$3.21K -6.64% Jul 31, 2023 10-K 2023-10-25
Q2 2022 $48.4K -$11K -18.5% Jul 31, 2022 10-K 2023-10-25
Q2 2021 $59.3K Jul 31, 2021 10-K 2022-10-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.